Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart
- PMID: 19076256
- DOI: 10.1111/j.1365-2605.2008.00932.x
Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart
Abstract
Erectile function is a haemodynamic phenomenon depending on the integrity of neurological, vascular, endocrinological, tissue (corpora cavernosa), psychological and relational factors; changes in any one of these components may lead to erectile dysfunction (ED). ED and its comorbid conditions share common risk factors such as endothelial dysfunction, atherosclerosis and metabolic and hormonal abnormalities. Furthermore, although cross-sectional studies have shown a clear age-dependent association between ED, diabetes mellitus, hypertension, metabolic syndrome (MetS) and cardiovascular diseases, longitudinal evidence has recently emphasized that ED could be an early marker of these conditions. Recently, the European Association of Urology and American Urology Association provided consensus guidelines for the management of ED patients. However, the metabolic aspect of ED is rather neglected or not sufficiently treated. In this study, more emphasis will be placed on the presence of ED comorbid metabolic factors. The primary and secondary goals of therapy, according to current guidelines and to prevent their clinical evolution, will also be provided. We review the concepts of metabolic diseases related to ED and their treatment. Criteria for the diagnosis and treatment of hypogonadism, metabolic and vascular disease related to ED were analysed. ED can mark the starting point for the evaluation and prevention of significant severe diseases (such as diabetes, MetS, dyslipidaemia, arteriosclerosis, hypertension, ischaemic cardiopathy, neuropathy, etc.) hitherto unknown by the patients. Most widely used criteria for the diagnosis and treatment of these diseases were reported. We suggest a clinical approach which allows the identification of metabolic and others systemic pathologies contributing to the development of ED. This approach may constitute an improvement in disease prognosis and either induce a spontaneous reduction of ED or facilitate its specific therapy.
Similar articles
-
Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links.Eur Urol. 2007 Dec;52(6):1590-600. doi: 10.1016/j.eururo.2007.08.004. Epub 2007 Aug 13. Eur Urol. 2007. PMID: 17707576 Review.
-
Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome.Aging Male. 2008 Dec;11(4):193-9. doi: 10.1080/13685530802468497. Aging Male. 2008. PMID: 19172551 Review.
-
Cardiovascular disease, metabolic syndrome and erectile dysfunction.Curr Opin Urol. 2006 Nov;16(6):435-43. doi: 10.1097/01.mou.0000250284.83108.a6. Curr Opin Urol. 2006. PMID: 17053524 Review.
-
[Clinical and diagnostic approach to erectile dysfunction].Ann Ital Med Int. 2003 Oct-Dec;18(4):204-18. Ann Ital Med Int. 2003. PMID: 14971709 Review. Italian.
-
The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction.J Androl. 2009 Jan-Feb;30(1):10-22. doi: 10.2164/jandrol.108.005215. Epub 2008 Jul 17. J Androl. 2009. PMID: 18641413 Review.
Cited by
-
Male sexual dysfunction and HIV--a clinical perspective.Nat Rev Urol. 2014 Feb;11(2):99-109. doi: 10.1038/nrurol.2013.314. Epub 2014 Jan 7. Nat Rev Urol. 2014. PMID: 24394405 Review.
-
"Mask up to keep it up": Preliminary evidence of the association between erectile dysfunction and COVID-19.Andrology. 2021 Jul;9(4):1053-1059. doi: 10.1111/andr.13003. Epub 2021 Mar 30. Andrology. 2021. PMID: 33742540 Free PMC article.
-
Erectile Dysfunction in Individuals with Neurologic Disability: A Hospital-based Cross-sectional Study.Innov Clin Neurosci. 2016 Feb 1;13(1-2):10-4. eCollection 2016 Jan-Feb. Innov Clin Neurosci. 2016. PMID: 27413582 Free PMC article.
-
Metabolic syndrome and erectile dysfunction: the ultrasound evaluation of cavernosal atherosclerosis.Diabetes Care. 2011 Aug;34(8):1875-7. doi: 10.2337/dc11-0070. Epub 2011 Jul 5. Diabetes Care. 2011. PMID: 21730283 Free PMC article.
-
Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo.J Endocrinol Invest. 2011 Nov;34(10):738-41. doi: 10.1007/BF03346724. J Endocrinol Invest. 2011. PMID: 22234177
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical